Pavel Krejci
Medical Genetics Institute
Cedars-Sinai Medical Center
Los Angeles
CA 90048
USA
Name/email consistency: high
- NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells. Krejci, P., Murakami, S., Prochazkova, J., Trantirek, L., Chlebova, K., Ouyang, Z., Aklian, A., Smutny, J., Bryja, V., Kozubik, A., Wilcox, W.R. J. Biol. Chem. (2010)
- Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. Krejci, P., Salazar, L., Kashiwada, T.A., Chlebova, K., Salasova, A., Thompson, L.M., Bryja, V., Kozubik, A., Wilcox, W.R. PLoS. ONE (2008)
- Simple, mammalian cell-based assay for identification of inhibitors of the Erk MAP kinase pathway. Krejci, P., Pejchalova, K., Wilcox, W.R. Invest. New. Drugs (2007)
- Bisindolylmaleimide I suppresses fibroblast growth factor-mediated activation of Erk MAP kinase in chondrocytes by preventing Shp2 association with the Frs2 and Gab1 adaptor proteins. Krejci, P., Masri, B., Salazar, L., Farrington-Rock, C., Prats, H., Thompson, L.M., Wilcox, W.R. J. Biol. Chem. (2007)
- Fibroblast growth factors 1, 2, 17, and 19 are the predominant FGF ligands expressed in human fetal growth plate cartilage. Krejci, P., Krakow, D., Mekikian, P.B., Wilcox, W.R. Pediatr. Res. (2007)